DMK PHARMACEUTICALS CORPORATION: 10-Q filed 2013-08-19

Name: DMK PHARMACEUTICALS CORPORATION: 10-Q filed 2013-08-19
Creator: DMK PHARMACEUTICALS CORPORATION

What DMK PHARMACEUTICALS CORPORATION reported in its quarterly report filed 2013-08-19 (fiscal Q1 2013): 19 published measures, 37 facts as tagged in accession 0001387131-13-003094.

This filing

Form: 10-Q (quarterly report)
Filed: 2013-08-19
Fiscal period: fiscal Q1 2013
Accession: 0001387131-13-003094 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All DMK PHARMACEUTICALS CORPORATION filings.

Reported measures

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2013-06-30	-4,975,388	USD
At 2013-03-31	-4,327,938	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-1,042,462	USD	91
2012-04-01 to 2012-06-30	-2,726,397	USD	91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-1,679,986	USD	91
2012-04-01 to 2012-06-30	-1,223,077	USD	91

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	5,093,508	USD	91
2012-04-01 to 2012-06-30	1,935,600	USD	91

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2013-06-30	-39,019,586	USD
At 2013-03-31	-37,977,124	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	71,512	USD	91

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-739,760	USD	91
2012-04-01 to 2012-06-30	-724,723	USD	91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2013-06-30	4,111,298	USD
At 2013-03-31	350,929	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	404,884	USD	91
2012-04-01 to 2012-06-30	294,965	USD	91

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2013-06-30	9,086,686	USD
At 2013-03-31	4,678,867	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2013-06-30	2,078,418	USD
At 2013-03-31	2,431,919	USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	515,244	USD	91
2012-04-01 to 2012-06-30	488,756	USD	91

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	224,516	USD	91
2012-04-01 to 2012-06-30	235,967	USD	91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2013-06-30	104,427,992	shares
At 2013-03-31	95,933,765	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2013-06-30	34,038,419	USD
At 2013-03-31	33,643,449	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2013-06-30	232,228	USD
At 2013-03-31	754,709	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2013-06-30	50,605	USD
At 2013-03-31	64,347	USD

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-302,702	USD	91
2012-04-01 to 2012-06-30	-2,001,674	USD	91

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-353,501	USD	91
2012-04-01 to 2012-06-30	-203,160	USD	91

Inspect the source

Entity: DMK PHARMACEUTICALS CORPORATION / CIK 0000887247
Captured: 2026-09-22 19:32 UTC
SEC response SHA-256: cc88d438258619b3d6acde0c3ef806d208e463a48f69c1a0310fac7d087cb187

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000887247.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))